Clinical Trial Update: P2Y12 Inhibitor Monotherapy Versus Extended DAPT in Patients Treated With Bioresorbable Scaffold [Phase 4]

View source ↗

Summary

Phase 4 trial comparing P2Y12 inhibitor monotherapy to extended dual antiplatelet therapy in patients with bioresorbable scaffolds; study status terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Coronary Artery Disease

Drugs mentioned

• P2Y12 inhibitor monotherapy

Snippet

Sponsor: Samsung Medical Center | Conditions: Coronary Artery Disease, Stents | Phase 4 | Status: TERMINATED